Leadership

Dr. Aixi Bai

Dr. Bai is the General Manager of Bestzyme, a Industrial synthetic biology products subsidiary of GenScript Biotech. Dr. Bai oversees comprehensive management duties, including production, research and development, business operations activities. Before he became the General Manager of Bestzyme in 2022, Dr. Bai was the Head of R&D at Bestzyme in 2018, where he was responsible for managing daily R&D operations. He joined Bestzyme in 2013 as a Senior Researcher, focusing on enzyme preparation project development.

Dr. Bai specializes in enzyme molecular discovery and enzyme engineering. He has 12 granted patents and patent applications, as well as 7 publications in peer-reviewed journals. Dr. Bai obtained his Bachelor's degree in Biological Sciences from Jilin University in 2005 and his Ph.D. in Microbiology from the same institution in 2012.

Aylin Kosova Bilgin

Mrs. Aylin Kosova Bilgin is the Chief Marketing Officer of GenScript Life Science. Aylin is a passionate marketing leader with more than 25 years of experience including 17 years at the Coca-Cola Company, where held several key leadership positions, including the ‘VP of Coca-Cola Trademark Category for Europe’ and ‘VP of Marketing Transformation for Latin America’. She played pivotal roles in supercharging growth, igniting new energy into marketing organizations, and redesigning structures, teams and capabilities, resulting in exceptional business and team performance. An accomplished marketing executive, her leadership significantly contributed to winning the Woodruff Cup – The Coca-Cola Company’s most prestigious award for the Best-In-Class Business Unit (BU).

Prior to joining GenScript, Aylin served as Chief Marketing Officer & Associate at The CMO Syndicate, where she partnered with executives providing executive marketing leadership, unlocking insights, and informing result-driving strategy to elevate top- and bottom-line performance, organizational design and capability across industries. Aylin continues to serve on the ‘CMO Syndicate AI Leadership Council’ and serves as an Angel Investor, Board Member, and Board Advisor for ‘Bounce Watch’, an AI-powered platform that delivers actionable real-time insights into startup performance and optimizes scouting process for venture capitalists.

Aylin holds a Bachelor’s degree in Business Administration from Marmara University. She is also an alumna of the “Inspirational Leadership Program” at IMD and the “Chief Marketing Officer Program” at Northwestern University’s Kellogg Executive Scholarship.

Dr. Ray Chen

Dr. Ray Chen has been with GenScript since 2012 and is the President of GenScript Life Science Group. He held positions at GenScript of increasing responsibilities including Sales and Technical support, Business development, Product development and Marketing, R&D and production operations. Currently, he leads GenScript Life Science group’s global commercial teams, R&D centers and manufacturing sites in China, Singapore and United States to provide reliable, high quality and innovative reagent products, custom services and instrument serving a wide variety of existing and emerging life science research and development areas. Before joining GenScript, he held positions in Fabric and Home care R&D at Proctor & Gamble in product design and development.

Dr. Chen studied peptide chemistry in Dr. Richard DiMarchi lab and earned his PhD in Chemistry from Indiana University Bloomington and BS in Chemistry from Nanjing University.

Mr. Allen Guo

Mr. Allen Guo is the CEO of Probio, a biologics CDMO subsidiary of the Company, and is in charge of Probio’s overall management.

After joining Probio, Mr. Guo served as the BD Head of China BD Department and was promoted to Assistant Vice President of the Asia-Pacific BD Department later, where he demonstrated leadership and cross-functional collaboration. He led the Asia-Pacific BD achieving outstanding performance, securing key milestone projects, and driving the advancement of multiple collaborative projects. Furthermore, he established mentorship program for high-potential talents, simplified and optimized business process, successfully built a cohesive, stable and high-performing BD team.

From May 2016 to December 2021, he served as BD Executive for APAC and BD Head for Greater China at Pharma Service Group, Thermo Fisher Scientific. From July 2014 to April 2016, he served as Strategic Alliance Manager for China at Diabetes Care, Becton Dickinson. From August 2010 to July 2014, he served as Key Account Manager at Industrial Solution, Lonza.

Mr. Guo obtained his Master degree in Macromolecular Chemistry and Physics from Fudan University in 2008.

Dr. Ying Huang

Dr. Ying Huang currently serves as the Chief Executive Officer of Legend Biotech, a material associate of GenScript. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics.

Dr. Huang brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr. Huang previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications.

Dr. Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

Dr. Raymond Miller

Dr. Raymond Miller is the Head of Corporate Communications. With over 12 years of experience in cross-functional communication, market research, strategy, and product development, Raymond has successfully led multiple global product management teams at GenScript. His notable achievements include building internal communication and information-sharing channels, establishing market intelligence programs, and launching nine nucleic acid reagent services.

Before joining GenScript, Raymond held various commercial and product management roles at Agilent Technologies and Bio-Rad Laboratories, where he took on increasing responsibilities. Key highlights from his tenure at these organizations include developing the SureSelect™ XT HS2 RNA Reagent Kit and globally launching the ChemiDoc™ MP Imaging system.

Dr. Raymond holds a PhD in Biochemistry and Molecular Biology from Virginia Tech.

Bhama Parimoo

Dr. Bhama Parimoo now serves as the Head of Global Diversity, Equity, and Inclusion(DEI). At GenScript, she has been instrumental in implementing the customer relationship platform and has contributed significantly to technical, sales, and business development efforts. In the Quality Assurance department, she addressed and resolved challenging issues, promoting our products and services to clients globally while receiving notable recognition. Her dedication and achievements have made her a three-time winner of the Best Employee of the Year award, in addition to receiving service awards.

After completing a postdoctoral fellowship at the University of Southern California School of Medicine, she worked as an Associate Research Scientist at the Yale School of Medicine and later served as a junior faculty member at Rutgers University before joining GenScript. She has published her work in peer-reviewed journals and presented at several conferences both in the US and internationally. Bhama holds a Ph.D. in Biochemistry and Molecular Biology from a prestigious research institute in India.

Sherry Shao

Ms. Sherry Shao currently serves as rotating chief executive officer of the Company and a member of the Sub-Committee on Data Security and Geopolitical Resilience under the Risk Management and ESG Committee. She has been appointed as a rotating CEO of the company with effect from January 1, 2023. She was appointed as the chief operating officer of the Company on July 8, 2021 and is primarily responsible for the supporting functions of the Company, including human resources, supply chain, engineering and instrument, information technology, quality and environmental, health and safety functions. She is also a member of the sanctions risk control committee.

Ms. Shao has over 17 years of management experience in the life-science and biologics development industry. Ms. Shao joined the Group in July 2005. From July 2005 to April 2017, Ms. Shao served in a number of positions at the Group, including a group leader of antibody department, a manager of antibody development and a vice president of reagent service production center. From April 2017 to April 2019, Ms. Shao worked as the deputy general manager of the reagent service business unit. From April 2019 to August 2020, Ms. Shao served as the president of life science group. From August 2020 to February 2021, she worked as the president of European division. From February 2021 to July 2021, she worked as China President. She was appointed as the chief operating officer of the Company in July 2021.

Ms. Shao, obtained her Bachelor of Science degree in biology from Nanjing Normal University in the PRC in June 2002 and a Master of Science degree in Preventive Veterinary from Yangzhou University in the PRC in June 2005.

Shiniu Wei

Mr. Shiniu Wei serves as the Chief Strategy Officer of the Company and a member of the Sub-Committee on Data Security and Geopolitical Resilience under the Risk Management and ESG Committee. Mr. Wei joined the Group in September 2019 as vice president of strategy and investor relations and then was promoted to CFO & VP of IR from December 2020. Mr. Wei has been appointed as CSO of the company from May 2025.

Prior to joining the Group, Mr. Wei worked as an executive director of secondary market investment department in Fosun Insurance Group in New York from 2017 to 2019. He served as an equity investment analyst and a portfolio manager in Investment Strategies Fund from 2010 to September 2016. From 2009 to May 2010, he worked as an analyst at Protocol Capital Management and prior to that, he worked as a researcher of Research Foundation at the City University of New York.

Mr. Wei obtained his Bachelor of Science degree in Biochemistry from Nanjing University in 2000 and his Master degree in Business Administration from Baruch College in 2011.

Josie Zhou

Josie Zhou has served as the interim CFO and VP of Finance at the Company since May 2025. Ms. Zhou joined the Group in 2017 as Senior Manager of Financial Planning & Analysis and successfully built the Financial Business Partner (BP) organization from the ground up. She later advanced to Finance Director of the Financial BP Center, where she managed key business finance operations.

Prior to joining the Group, Ms. Zhou spent nearly nine years at Deloitte, working in the Audit Department. Rising from Auditor to Audit Manager, she gained extensive expertise in financial auditing. In 2010, she completed a one-year international assignment at Deloitte Singapore, further broadening her global exposure.

Ms. Zhou holds a Bachelor’s degree in Finance from Shandong University (Weihai) and a Master’s degree in Management from Hohai University. She is also a Certified Public Accountant in China.